Cellgram-LC
Phase 3Biologic
Cellgram-LC is one of 37 biologic programs targeting Alcoholic Liver Cirrhosis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
252 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Cellgram-LC
PPharmicell Co., Ltd.
Phase 3
Proamatine
TakedaPreclinical
Crestor
AstraZenecaPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Azulfidine
PfizerPreclinical
Dobutrex
Eli LillyPreclinical
HEPCLUDEX
GileadPreclinical
Cipro
BayerPreclinical
Revia
TevaPreclinical
Coreg
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cellgram-LC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- PPharmicell Co., Ltd.